Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...